Insulin resistance in the metabolic syndrome

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

Standard

Insulin resistance in the metabolic syndrome. / Biddinger, Sudha B.; Emanuelli, Brice.

Metabolic Basis of Obesity. Springer New York LLC, 2011. p. 175-198.

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Communication

Harvard

Biddinger, SB & Emanuelli, B 2011, Insulin resistance in the metabolic syndrome. in Metabolic Basis of Obesity. Springer New York LLC, pp. 175-198. https://doi.org/10.1007/978-1-4419-1607-5_10

APA

Biddinger, S. B., & Emanuelli, B. (2011). Insulin resistance in the metabolic syndrome. In Metabolic Basis of Obesity (pp. 175-198). Springer New York LLC. https://doi.org/10.1007/978-1-4419-1607-5_10

Vancouver

Biddinger SB, Emanuelli B. Insulin resistance in the metabolic syndrome. In Metabolic Basis of Obesity. Springer New York LLC. 2011. p. 175-198 https://doi.org/10.1007/978-1-4419-1607-5_10

Author

Biddinger, Sudha B. ; Emanuelli, Brice. / Insulin resistance in the metabolic syndrome. Metabolic Basis of Obesity. Springer New York LLC, 2011. pp. 175-198

Bibtex

@inbook{a712e19b7408426f8ed3b375bf862bb7,
title = "Insulin resistance in the metabolic syndrome",
abstract = "In 1988, Gerald Reaven coined the term Syndrome X to describe a complex of metabolic abnormalities, including glucose intolerance, hypertriglyceridemia and reduced levels of HDL-cholesterol, present in individuals at increased risk for cardiovascular disease [1]. Since then, attempts to quantify cardiovascular disease risk have led to the development of clinical criteria for the diagnosis of this syndrome, now known as the metabolic syndrome or insulin resistance syndrome. Although these criteria continue to evolve, those put forth by the National Cholesterol Education Program (NCEP), World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), International Diabetes Federation (IDF) and American Association of Clinical Endocrinologists (AACE), all include hyperglycemia, hypertriglyceridemia, low HDL-cholesterol and hypertension (reviewed in [2)] (Table 1). It is clear now that the metabolic syndrome is associated with many diseases in addition to cardiovascular disease. These include cholesterol gallstones, non-alcoholic fatty liver disease, which ranges from benign steatosis to non-alcholic steatohepatitis (NASH), polycystic ovary disease (PCOS) and neurodegenerative disease.",
author = "Biddinger, {Sudha B.} and Brice Emanuelli",
year = "2011",
month = dec,
day = "1",
doi = "10.1007/978-1-4419-1607-5_10",
language = "English",
isbn = "9781441916068",
pages = "175--198",
booktitle = "Metabolic Basis of Obesity",
publisher = "Springer New York LLC",

}

RIS

TY - CHAP

T1 - Insulin resistance in the metabolic syndrome

AU - Biddinger, Sudha B.

AU - Emanuelli, Brice

PY - 2011/12/1

Y1 - 2011/12/1

N2 - In 1988, Gerald Reaven coined the term Syndrome X to describe a complex of metabolic abnormalities, including glucose intolerance, hypertriglyceridemia and reduced levels of HDL-cholesterol, present in individuals at increased risk for cardiovascular disease [1]. Since then, attempts to quantify cardiovascular disease risk have led to the development of clinical criteria for the diagnosis of this syndrome, now known as the metabolic syndrome or insulin resistance syndrome. Although these criteria continue to evolve, those put forth by the National Cholesterol Education Program (NCEP), World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), International Diabetes Federation (IDF) and American Association of Clinical Endocrinologists (AACE), all include hyperglycemia, hypertriglyceridemia, low HDL-cholesterol and hypertension (reviewed in [2)] (Table 1). It is clear now that the metabolic syndrome is associated with many diseases in addition to cardiovascular disease. These include cholesterol gallstones, non-alcoholic fatty liver disease, which ranges from benign steatosis to non-alcholic steatohepatitis (NASH), polycystic ovary disease (PCOS) and neurodegenerative disease.

AB - In 1988, Gerald Reaven coined the term Syndrome X to describe a complex of metabolic abnormalities, including glucose intolerance, hypertriglyceridemia and reduced levels of HDL-cholesterol, present in individuals at increased risk for cardiovascular disease [1]. Since then, attempts to quantify cardiovascular disease risk have led to the development of clinical criteria for the diagnosis of this syndrome, now known as the metabolic syndrome or insulin resistance syndrome. Although these criteria continue to evolve, those put forth by the National Cholesterol Education Program (NCEP), World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), International Diabetes Federation (IDF) and American Association of Clinical Endocrinologists (AACE), all include hyperglycemia, hypertriglyceridemia, low HDL-cholesterol and hypertension (reviewed in [2)] (Table 1). It is clear now that the metabolic syndrome is associated with many diseases in addition to cardiovascular disease. These include cholesterol gallstones, non-alcoholic fatty liver disease, which ranges from benign steatosis to non-alcholic steatohepatitis (NASH), polycystic ovary disease (PCOS) and neurodegenerative disease.

UR - http://www.scopus.com/inward/record.url?scp=84877587761&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1607-5_10

DO - 10.1007/978-1-4419-1607-5_10

M3 - Book chapter

AN - SCOPUS:84877587761

SN - 9781441916068

SP - 175

EP - 198

BT - Metabolic Basis of Obesity

PB - Springer New York LLC

ER -

ID: 200864032